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Abstract The clinically useful anticancer drug mitoxantrone in- 
tercalates preferentially into 5'-(A/T)CG and 5'-(AfF)CA sites on 
DNA. The 5,8 hydroxyl substituents on its anthracenedione chro- 
mophore are available to interact with the double befix. Foot- 
printing experiments with two anthraquinone derivatives tructur- 
ally related to mitoxantrone and ametantrone have been under- 
taken to assess the influence of the hydroxyl groups on the DNA 
recognition process. The results confirm that they do play a role 
in the recognition of preferred nucleotide sequences and suggest 
that the binding of anthraquinones to a 5'-(MT)CG site is depend- 
ent on the presence of the 5,8 hydroxyl substituents whereas 
binding to 5'-(A/T)CA sites appears to proceed just as well with- 
out them. 
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In addition, it has been postulated that the hydroxyl groups at 
positions 5 and 8 on the anthraquinone chromophore might 
also contribute to the interaction because mitoxantrone dissoci- 
ates more slowly from DNA than does its non-hydroxylated 
homologue ametantrone [15]. Various studies comparing the 
DNA binding properties of mitoxantrone and ametantrone 
concur that the 5,8-(OH)2 groups stabilize the drug-DNA com- 
plex [3,13,21]. To elucidate the role of these phenolic hydroxyl 
substituents we have investigated the sequence-specific re ogni- 
tion of DNA by two mitoxantrone analogues which both lack 
the hydroxyethyl groups on the aminoalkyl side chains and 
differ by the presence or the absence of hydroxyl substituents 
at positions 5 and 8 (Fig. 1). DNase I footprinting experiments 
suggest that the hydroxyl groups are involved in the recognition 
of 5'-(A/T)CG trinucleotides but not of 5'-(A/T)CA. 
2. Materials and methods 
1. Introduction 
The synthetic antitumour drug mitoxantrone (Fig. 1) has 
major clinical value in the treatment of several leukemias as well 
as solid tumours uch as breast cancer because it is less cardi- 
otoxic than the classical anthracycline antibiotics [1,2]. This 
1,4-[bis-(aminoalkyl)amino]-anthracene-9,10-dione derivative 
binds to cellular nucleic acids, causes chromatin compaction, 
produces damaging radicals and interferes with topoisomerase 
II activity so as to induce DNA strand breaks [3-7]. The inter- 
action with DNA and consequent damage are thought o be 
essential for its therapeutic effect [8,9]. 
Spectroscopic studies originally showed that mitoxantrone 
binds preferentially to GC-rich DNA and synthetic polynucle- 
otides [10-15]. A preference for alternating purine-(3',5')-py- 
rimidine sequences was subsequently inferred from foot- 
printing and theoretical studies [16,17]. More recently, selective 
recognition of 5'-(A/T)CG and 5'-(A/T)CA trinucleotides was 
deduced from in vitro transcription assays [18]. Although the 
molecular determinants implicated in DNA recognition by mi- 
toxantrone have yet to be identified, it is believed that the two 
hydroxyethylaminoalkyl side chains are, at least in part, re- 
sponsible for its sequence selectivity since the length, position 
and nature of these positively charged side chains strongly 
influence the stability of drug-DNA complexes [13,15,19,20]. 
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2.1. Drugs 
Compounds A and B were prepared by condensation of leuco- 
quinizarine or 5,8-dihydroxyleucoquinizarine with t-Boc-ethylenedi- 
amine followed by air oxidation of the dihydro intermediates a previ- 
ously described [22,23]. Stock solutions were prepared in 10 mM Tris- 
HC1 buffer containing 10 mM NaC1 (pH 7.0) and stored at 4°C. 
2.2. Viscometry 
Viscosity measurements were carried out using a specially con- 
structed capillary viscometer as previously described [24]. Unwinding 
angles were estimated with reference to that of ethidium bromide (26 °) 
used as a control [25]. 
2.3. DNA fragments 
The 117 bp fragment was cut out of plasmid pBS with EcoRI and 
PvuII and 3'-end labelled at the EcoRI site with [a-32p]dATP in the 
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Fig. 1. Structures of anthracenedione drugs. 
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presence of AMV reverse transcriptase, tyrT(A93) DNA was cut out 
of plasmid pKMp27 with EcoRI and AvaI and 5'-end labelled with 
[~'-s2p]ATP in the presence ofT4 polynucleotide kinase [26,27]. Mole- 
cules ubstituted with inosine and/or DAP were prepared by pcr [27]. 
Labelled DNA was purified by 6% polyacrylamide g lelectrophoresis 
prior to being resuspended in 10 mM Tris-HCl, pH 7.0 buffer contain- 
ing 10 mM NaCI. 
2.4. DNase I footprinting 
DNase I experiments were performed essentially according to the 
original protocol [28]. Briefly, the digestion of 6 pl samples of the 
labelled DNA fragment was initiated by adding 2 pl of a DNase I 
solution so as to yield a final enzyme concentration of about 0.01 
unit/ml. After 3 min, the digestion was stopped by freeze drying, sam- 
ples were lyophilized, washed once with 50/tl of water, lyophilized 
again and then resuspended in 4/11 of an 80% formamide solution 
containing tracking dyes. Samples were heated at 90°C for 4 min and 
chilled in ice for 4 min prior to electrophoresis. 
2.5. Electrophores& and quantitation by storage phosphor imag&g 
DNA cleavage products were resolved by polyacrylamide gelelectro- 
phoresis under denaturing conditions (0.3 mm thick, 8% acrylamide 
containing 8 M urea). After electrophoresis (about 2.5 hours at 60 
Watts, 1600 V in TBE buffer, BRL sequencer model $2), gels were 
soaked in 10% acetic acid for 15 min, transferred toWhatman 3MM 
paper, dried under vacuum at 80°C, and examined by autoradiography 
using either a phosphorimager or X-ray films (Fuji R-X) exposed at 
-70°C with an intensifying screen. For quantitative analysis, a Molec- 
ular Dynamics 425E Phosphorlmager was used to collect data from 
storage screens exposed to the dried gels overnight at room tempera- 
ture. Base line-corrected scans were analyzed by integrating all the 
densities between two selected boundaries using ImageQuant version 
3.3 software. 
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3. Results and discussion 
Prior to investigating sequence specific binding to DNA, 
viscometric measurements using closed circular duplex DNA 
were performed in order to compare the effects of the two 
anthraquinone d rivatives on DNA supercoiling. Both drugs 
unwind the double helix to a similar extent. The unwinding 
angle, measured by titrating drug into supercoiled DNA at 
various concentrations, was estimated to be 16 ° for compound 
A and 15 ° for compound B respectively. Similar unwinding 
angles have been reported for mitoxantrone and structurally 
related anthraquinones [11,19,29] confirming that both deriva- 
tives A and B can also intercalate into DNA. 
In the first series of footprinting experiments, performed with 
a 117 bp restriction fragment from plasmid pBS in the presence 
of increasing concentrations of compounds A and B, the cleav- 
age pattern differs substantially from that in the control sam- 
ples (Fig. 2) suggesting that both ligands are capable of interact- 
ing with DNA in a sequence-selective fashion. At 5 ~tM the 
involvement of a specific binding process can easily be seen by 
the blockage of nuclease activity around nucleotide positions 
31, 55 and 74. The ratio of fractional cleavage in the presence 
of drug to that in the drug-free control was calculated for each 
internucleotide linkage and used to construct differential c eav- 
age plots (Fig. 3). They reveal that a feature common to both 
drugs is the enhancement of cutting by DNase I at phospho- 
diester bonds between bases 62-69 and 80-90 indicating that 
binding to AT-rich sequences i disfavoured, just as reported 
with mitoxantrone [16]. Similarly, GC-containing ho- 
mopurine.homopyrimidine tracts do not afford binding sites 
for compounds A and B since in neither case are the trinucleo- 
tides GGG and CCC at positions 61, 68 and 79 protected from 
Fig. 2. DNase I footprinting with the 117-mer f agment inthe presence 
of compound A (left panel) and B (right panel) at concentrations ~M) 
shown at the top of each gel lane. The control tracks labelled 'Ct' 
contained no drug. The tracks labelled T+C, G+A and G represent 
Maxam-Gilbert sequencing markers pecific for pyrimidine, purine, 
and guanine residues respectively. Numbers refer to the nucleotide 
sequence shown in Fig. 3. 
attack. The two drugs bind preferentially toalternating purine- 
pyrimidine sequences containing both A.T and G.C base 
pairs. With the dihydroxy-anthraquinone derivative A every 
region protected from DNase I cleavage (a presumptive drug 
binding site) lies squarely around the trinucleotide ACG or 
5'-(A/T)CA (which is equivalent to 5'-TG(A/T)), marked re- 
spectively by black and hatched rectangles in Fig. 3A. 5'-(A/ 
T)CG or 5'-(A/T)CA triplets are the consensus sequences re- 
ported for mitoxantrone [18]. This observation immediately 
establishes that the hydroxyethyl terminal groups which distin- 
guish mitoxantrone from compound A are not responsible for 
the sequence- selective recognition process. 
The sequences which are protected from DNase I cleavage 
by compound B are comparable to but distinct from those 
C Bailly et al. IFEBS Letters 379 (1996) 269-272 271 
I - -  0.51.~I . . . . .  lpM ... . . . . . . .  2 .5pM 5pM 
2 • • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
5 '_AGGCGATTAAGTTGGGTARCGCCAGGGTTTTCCCAGTCRCGACGTTGTAAARCGACGGCCAGTGAATTGTA ATR 
90 80 70 60 50 40 30 20 
2 
A M £ 
c5 
5 ' -AGGCGATTARGTTGGGTAACGCCAGGGTTTTCCCAGTCACGRCGTTGIAAAACGACGGCCRGTGAATTGTAAI  
90 80 70 60 50 40 30 20 
Fig. 3. Differential cleavage plots showing differences in susceptibility of the 117-mer f agment to DNase I cleavage in the presence of drugs A (top 
panel) and B (bottom panel). Vertical scales are in units of ln~,)- ln(fc), where fa is the fractional cleavage at any bond in the presence of the drug 
and f~ is the fractional cleavage of the same bond in the control. Negative values correspond toa ligand-protected site and positive values represent 
enhanced cleavage. Black boxes indicate the triplet sequences 5'-ACG. Hatched boxes mark the triplets 5'-AGT or 5'-TCA. 
protected by compound A. There is rather poor correspond- 
ence between the drug B-protected sites and the ACG triplets. 
On the other hand, there is a relatively good correspondence 
with the sites containing a CA or TG step such as the trinucle- 
otides CCA, TCA and TGT marked as hatched rectangles in 
Fig. 3B. Therefore, the results suggest that binding to a 5'-(A/ 
T)CG site is dependent on the presence of the 5,8 hydroxyl 
groups on the anthracenedione chromophore whereas binding 
to 5'-(A/T)CA sites proceed to a large extent irrespective of the 
presence or absence of hydroxyl groups. 
The generality of these observations has been confirmed with 
the 160 bp tyrT(A93) DNA fragment which was previously 
employed to study the sequence specificity of mitoxantrone [16] 
as well as a variety of other DNA-binding drugs [30]. This DNA 
fragment offers weaker binding sites for the anthraquinones 
than the 117-mer. However, the differential cleavage plots 
shown in Fig. 4 corroborate the conclusions drawn with the 
pBS fragment. The regions of reduced nuclease cleavage in the 
presence of compounds A and B match quite well, though not 
exclusively, with CG- or CA (TG)-containing sites. In most 
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Fig. 4. Nuclease cleavage of tyrT(A93) DNA containing natural nucleotides, inosine in place of guanosine, DAP in place of adenine, or both inosine 
and DAP, in the presence of 5/.tM drugs A and B. Other details as for Fig. 3. 
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cases, footprints at XCG sites (black rectangles) are observed 
with the bis-hydroxylated compound A whereas they are less 
pronounced or absent with the non-hydroxylated analogue B. 
This is particularly noticeable around the sequence 
ACGCGCCG extending from positions 80 to 73 which denotes 
a strong binding site for drug A but not for drug B. Conversely, 
footprints at CA or TG steps are detected almost identically 
with compounds A and B. 
Finally, the influence of a structural modification which af- 
fects the minor groove of the DNA helix was examined, namely 
the effect of transposing the purine 2-amino group from gua- 
nine to adenine nucleotides [27]. Both compounds A and B were 
found to footprint on the modified DNA molecules in much the 
same way as they do on natural tyrT DNA (Fig. 4), showing 
that sequence recognition by these molecules cannot depend 
upon interaction with the 2-amino group of guanine located in 
the minor groove. This is consistent with an intercalation proc- 
ess which would leave the alkylamine side chains sitting in the 
major groove, as is believed to be the case for mitoxantrone [I 8] 
and bis-naphthalimide rugs [25]. 
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